The Europe In Vitro Diagnostics (IVD) market plays a crucial role in the region’s healthcare landscape, encompassing a wide range of diagnostic tests and technologies used for disease detection, ...

Request To Download Free Sample of This Strategic Report@ Highlighted with 25 tables and 60 figures, this 131-page report North America In Vitro Diagnostics (IVD) Market 2021-2031 by Product ...

Judge José Luis Calama of the National Court, who is investigating the Grifols case, has asked the National Securities Market Commission ...

Some of Grifols SA ’s board members could be sanctioned for the Spanish drug maker’s accounting deficiencies as the company readies to face off short seller Gotham City Research in a Madrid court.

Regulator says Gotham City attacks could be manipulation CNMV also says short seller right on some accounting issues Drugmaker Grifols SA and US short seller Gotham City Research are counting on two ...

(Bloomberg) -- Drugmaker Grifols SA and US short seller Gotham City Research are counting on two different reports from a Spanish regulator to bolster their cases as they prepare to face off in court.

The local subsidiary of Servier is under new leadership in Argentina. Bruno Schwintner has stepped in after the departure of Nelson Da Conceiçao. The Frenchman already has experience in Latin America.

Spanish pharma Grifols is leveraging its massive collection of plasma samples to look for early biomarkers of Parkinson’s disease (PD) thanks to a $21 million grant from the Michael J.

Initiative aims to identify plasma-based biomarkers for early detection Grifols has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based ...

Grifols, a global healthcare company and producer of plasma-derived medicines, has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based ...

MADRID (Reuters) - U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding more transparency from the embattled pharmaceutical ...

"We urge the CNMV to consider the benefits to all Grifols shareholders from improved disclosure," Mason Capital said. The CNMV declined to comment about the letter. Grifols shares were down around ...